On January 9, 2026 Link Cell Therapies ("Link"), an oncology cell therapy company, reported a strategic collaboration with Johnson & Johnson* to develop novel logic-gated LINK CAR T therapies. The collaboration follows the recently announced Series A financing in Link that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc, which included participation of additional strategic and financial investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration aims to develop AND-gate CAR T programs for clinical use by leveraging Link’s proprietary LINK logic gate, a novel technology that allows for the safe and potent killing of tumor cells. Prior CAR T efforts targeting multiple tumor types have been limited by toxicity resulting from killing of healthy tissue cells expressing target antigens. LINK CAR T cells have the potential to overcome this challenge by selectively targeting proteins that are co-expressed on tumor cells (but not healthy tissues), thereby dramatically expanding the world of tumor specific cancer antigens.

"We are excited for this collaboration to expand the pipeline of LINK CAR T programs," said Mark Wallet, Ph.D., Chief Scientific Officer of Link Cell Therapies. "Our proprietary LINK platform is broadly applicable against cancer antigens for indications with high levels of patient need; we look forward to advancing a new generation of impactful CAR T therapies via internal development and strategic partnerships."

(Press release, Link Cell Therapies, JAN 9, 2026, View Source [SID1234661898])